Nonclinical safety strategies for stem cell therapies

被引:44
|
作者
Sharpe, Michaela E. [1 ]
Morton, Daniel [2 ]
Rossi, Annamaria [1 ]
机构
[1] Pfizer Ltd, Drug Safety Res & Dev, Investigat Toxicol, Sandwich CT13 9NJ, Kent, England
[2] Pfizer Inc, Drug Safety Res & Dev, Exploratory Drug Safety, Cambridge, MA 02140 USA
关键词
Stem cells; Biodistribution; Immunogenicity; Tumorigenicity; Toxicology; Safety studies; HUMAN BONE-MARROW; PROGENITOR CELLS; IMMUNOLOGICAL-PROPERTIES; TERATOMA FORMATION; CLINICAL-TRIALS; STROMAL CELLS; TRANSPLANTATION; ENGRAFTMENT; EXPRESSION; DIFFERENTIATION;
D O I
10.1016/j.taap.2012.05.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Recent breakthroughs in stem cell biology, especially the development of the induced pluripotent stem cell techniques, have generated tremendous enthusiasm and efforts to explore the therapeutic potential of stem cells in regenerative medicine. Stem cell therapies are being considered for the treatment of degenerative diseases, inflammatory conditions, cancer and repair of damaged tissue. The safety of a stem cell therapy depends on many factors including the type of cell therapy, the differentiation status and proliferation capacity of the cells, the route of administration, the intended clinical location, long term survival of the product and/or engraftment, the need for repeated administration, the disease to be treated and the age of the population. Understanding the product profile of the intended therapy is crucial to the development of the non-clinical safety study design. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:223 / 231
页数:9
相关论文
共 50 条
  • [1] Nonclinical safety assessment of engineered T cell therapies
    Lebrec, Herve
    Maier, Curtis C.
    Maki, Kazushige
    Ponce, Rafael
    Shenton, Jacintha
    Green, Shon
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2021, 127
  • [2] Cell augmentation strategies for cardiac stem cell therapies
    Cruz-Samperio, Raquel
    Jordan, Millie
    Perriman, Adam
    STEM CELLS TRANSLATIONAL MEDICINE, 2021, 10 (06) : 855 - 866
  • [3] Comparison of Genetically Engineered Immunodeficient Animal Models for Nonclinical Testing of Stem Cell Therapies
    Kim, Yoon-Young
    Kim, Jin-Soo
    Che, Jeong-Hwan
    Ku, Seung-Yup
    Kang, Byeong-Cheol
    Yun, Jun-Won
    PHARMACEUTICS, 2021, 13 (02) : 1 - 19
  • [4] Regulatory Consideration for the Nonclinical Safety Assessment of Gene Therapies
    Moffit, Jeffrey. S. S.
    Blanset, Diann. L. L.
    Lynch, Jessica. L. L.
    MacLachlan, Timothy. K. K.
    Meyer, Kathleen. E. E.
    Ponce, Rafael
    Whiteley, Laurence. O. O.
    HUMAN GENE THERAPY, 2022, 33 (21-22) : 1126 - 1141
  • [5] A Cell Engineering Strategy to Enhance the Safety of Stem Cell Therapies
    Oricchio, Elisa
    Papapetrou, Eirini P.
    Lafaille, Fabien
    Ganat, Yosif M.
    Kriks, Sonja
    Ortega-Molina, Ana
    Mark, Willie H.
    Teruya-Feldstein, Julie
    Huse, Jason T.
    Reuter, Victor
    Sadelain, Michel
    Studer, Lorenz
    Wendel, Hans-Guido
    CELL REPORTS, 2014, 8 (06): : 1677 - 1685
  • [6] Tolerance strategies for stem-cell-based therapies
    Chidgey, Ann P.
    Layton, Daniel
    Trounson, Alan
    Boyd, Richard L.
    NATURE, 2008, 453 (7193) : 330 - 337
  • [7] Tolerance strategies for stem-cell-based therapies
    Ann P. Chidgey
    Daniel Layton
    Alan Trounson
    Richard L. Boyd
    Nature, 2008, 453 : 330 - 337
  • [8] Combinatorial suicide gene strategies for the safety of cell therapies
    Falcon, Corey
    Smith, Lauren
    Al-Obaidi, Mustafa
    Abu Zaanona, Mohammed
    Purvis, Katelyn
    Minagawa, Kentaro
    Athar, Mohammad
    Salzman, Donna
    Bhatia, Ravi
    Goldman, Frederick
    Di Stasi, Antonio
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [9] Emerging Stem Cell Therapies: Treatment, Safety, and Biology
    Sng, Joel
    Lufkin, Thomas
    STEM CELLS INTERNATIONAL, 2012, 2012
  • [10] Current nonclinical evaluation of immune-related safety risks for engineered T cell therapies
    Lebrec, H.
    TOXICOLOGY LETTERS, 2021, 350 : S52 - S52